In a phase II trial, 60 patients with advanced NSCLC with HER2 exon 20 mutations who had disease progression after platinum-based chemotherapy were enrolled to receive pyrotinib 400 mg once daily. Here, ERBB2 is linked to non-small cell lung carcinoma.